玉郎伞多糖对双氯芬酸钠、尼美舒利、布洛芬致小鼠肝损伤的保护作用
|
摘要
目的：
探讨玉郎伞多糖对双氯芬酸钠(Diclofenac sodium，DICF)、尼美舒利(Nimesulide，NIM)、布洛芬(Ibuprofen，IBU)致小鼠肝损伤的保护作用及其机制研究。
方法：
1.实验动物分组、给药及模型建立
把昆明种小鼠随机分为正常对照组(NC)，损伤模型组，YLSPS高剂量组(YLSPSH，600mg/kg)，YLSPS中剂量组(YLSPSM，300mg/kg)，YLSPS低剂量组(YLSPSL，150mg/kg)和联苯双酯组(200mg/kg，DDB)。以联苯双酯为阳性对照药和YLSPS高、中、低剂量组治疗，每日灌胃给药一次。除正常组给相等容量生理盐水外，其余所有小鼠给予相应的致肝损伤药物，每日一次，连续10天(尼美舒利)，14天(双氯芬酸钠、布洛芬)。实验结束前动物禁食20h，取血及脏器进行检测肝功能指标。
2.计算肝脏重量指数，脾脏重量指数
3. HE染色观察各组小鼠肝细胞损伤程度
4.在DICF模型中，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总胆红素（Total bilirubin, TBIL)的含量及血清中肿瘤坏死因子-α（TNF-α)、白介素-1β (IL-1β)及肝脏超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)和过氣化氢酶(CAT)的水平。实时荧光定量PCR方法检测肝组织Bax、Bc1-2基因的mRNA表达。
5.在NIM模型中，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总抗氧化能力(Tota1antioxide capacity，T-AOC)，血清肿瘤坏死因子-α（TNF-α)、白介素-6(IL-6)及肝脏超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)及丙二醛(MDA)含量。Westem-Blot检测Bax、Bc1-2蛋白表达。
6.在IBU模型中，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总抗氧化能力（Tota1antioxide capacity，T-AOC）及肝脏超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)及丙二醛(MDA)含量。Westem-Blot检测和免疫组化技术检测各组小鼠肝组织Bax、Bc1-2蛋白的表达。
结果：
1.在DICF模型中，与模型组比较，YLSPS各剂量组用能降低肝脏指数和脾脏指数；可降低血清ALT、AST、ALP、TBIL水平和肝组织MDA含量；降低血清中TNF-α与IL-1β；提高肝组织SOD、CAT、GSH-Px活性（P<0.05）；病理切片结果表明YLSPS各剂量组能够不同程度地减轻肝细胞的损伤程度。YLSPS能降低Bax mRNA的表达；增加肝组Bcl-2mRNA的表达(P<0.05)。
2.在NIM模型中，与模型组比较，YLSPS各剂量组能降低肝脏指数和脾脏指数；可降低血清ALT、AST、ALP和肝组织MDA含量；降低血清TNF-α与IL-6；提高血清T-AOC水平和肝组织SOD、GSX-Px活性（P<0.05）；病理切片结果表明YLSPS各组能够不同程度地减轻肝细胞的损伤程度。YLSPS能降低Bax蛋白表达；增加肝组织Bcl-2蛋白表达(P<0.05)。
3.在IBU模型中，与模型组比较，YLSPS各剂量组能降低肝脏指数和脾脏指数；可降低血清ALT、AST、ALP和肝组织MDA含量；提高血清T-AOC水平和肝组织SOD、GSX-Px活性（P<0.05）；病理切片结果表明YLSPS各组能够不同程度地减轻肝细胞的损伤程度。YLSPS能降低Bax蛋白表达；增加肝组织Bcl-2蛋白表达(P<0.05)。
结论：
YLSPS对双氯芬酸钠、尼美舒利和布洛芬所致小鼠肝损伤具有保护作用，其机制可能与其抗氧自由基、抑制脂质过氧化、抑制细胞凋亡作用有关。
Objective： To observe the protective effect of Yulangsan Polysaecharide(YLSPS) on diclofenac sodium，nimesulide and ibuprofen-induced liver injuryin Kunming mice.
Method：
1.Animal and treatment
Kunming mice were randomly divided into NC group，liver injured modelgroup with， high-，middle-，low-YLSPS group (600，300，150mg/kg) anddimethyl diphenyl bicarboxylate (200mg/kg DDB) group. The treatment groupswere orally administered once per day，whereas the normal and model groupswere orally administered with saline. Except normal mice, all the other micewere treated with drug induced liver injury for10days (nimesulide),14days(diclofenac, ibuprofen). At the end of the experimental period the mice were sacrificed and blood, liver samples were obtained.
2.The indexs of the liver and spleen were observed
3.Hematoxylineosin (HE) stain was used to examine the degree of hepaticinjury.
4.Diclofenac sodium model：Estimation of ALT，AST and ALP, the content ofTBIL, TNF-α and IL-1β in serum and the activities of SOD, GSH–Px and CAT，the content of MDA in liver tissue. The levels of expression of Bax and Bcl-2mRNA in liver were examined by Real-time quantitative-PCR.
5. Nimesulide model：Estimation of ALT，AST, ALP and T-AOC，the contentof TNF-α，IL-6in serum；the activities of SOD，GSH–Px and the content ofMDA in liver tissue. The expressions of Bax and Bcl-2in liver were detected byWestern Blot.
6.Ibuprofen model：Estimation of of ALT，AST and ALP，the content ofT-AOC in serum；the activities of SOD，GSH-Px and the content of MDA inliver tissue were investigated. The expressions of Bax and Bcl-2in liver weredetected by immunohistochemical and Western Blot.
Results：
1.Diclofenac model： Compared with model group, YLSPS could obviouslyreduce the weight of the liver and spleen. The activities of ALT，AST andALP，the content of TBIL，MDA，TNF-α and IL-1β and the expression ofBax could be decreased. The activities of SOD，GSH-Px，CAT and theexpression of Bcl-2could be increased (P<0.05), and the degree of hepaticinjury could be lessened.
2.Nimesulide model：Compared with model group， YLSPS could obviouslyreduce the activities of ALT，AST and ALP，the content of MDA，TNF-α， IL-6the index of liver, spleen and the expression of Bax. The activities ofSOD，GSH-Px，T-AOC and the expression of Bcl-2could be increased(P<0.05)；the degree of hepatic injury could be lessened.3.Ibuprofen model：Compared with model group，YLSPS could be decreasedthe index of liver and spleen，the activities of ALT，AST and ALP，the contentof MDA and the expression of Bax. The activities of SOD，GSH-Px，T-AOCand the expression of Bcl-2could be increased (P<0.05); the degree of hepaticinjury could be lessened.
Conclusion：
YLSPS has protective effect on diclofenac sodium, nimesulide andibuprofen-induced liver injury in mice. The mechanism may be related toattenuating free radical and inhibiting the effect on lipid peroxidation andapoptosis.
探讨玉郎伞多糖对双氯芬酸钠(Diclofenac sodium，DICF)、尼美舒利(Nimesulide，NIM)、布洛芬(Ibuprofen，IBU)致小鼠肝损伤的保护作用及其机制研究。
方法：
1.实验动物分组、给药及模型建立
把昆明种小鼠随机分为正常对照组(NC)，损伤模型组，YLSPS高剂量组(YLSPSH，600mg/kg)，YLSPS中剂量组(YLSPSM，300mg/kg)，YLSPS低剂量组(YLSPSL，150mg/kg)和联苯双酯组(200mg/kg，DDB)。以联苯双酯为阳性对照药和YLSPS高、中、低剂量组治疗，每日灌胃给药一次。除正常组给相等容量生理盐水外，其余所有小鼠给予相应的致肝损伤药物，每日一次，连续10天(尼美舒利)，14天(双氯芬酸钠、布洛芬)。实验结束前动物禁食20h，取血及脏器进行检测肝功能指标。
2.计算肝脏重量指数，脾脏重量指数
3. HE染色观察各组小鼠肝细胞损伤程度
4.在DICF模型中，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总胆红素（Total bilirubin, TBIL)的含量及血清中肿瘤坏死因子-α（TNF-α)、白介素-1β (IL-1β)及肝脏超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)和过氣化氢酶(CAT)的水平。实时荧光定量PCR方法检测肝组织Bax、Bc1-2基因的mRNA表达。
5.在NIM模型中，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总抗氧化能力(Tota1antioxide capacity，T-AOC)，血清肿瘤坏死因子-α（TNF-α)、白介素-6(IL-6)及肝脏超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)及丙二醛(MDA)含量。Westem-Blot检测Bax、Bc1-2蛋白表达。
6.在IBU模型中，测定血清谷丙转氨酶(ALT)、谷草转氨酶(AST)、碱性磷酸酶(ALP)、总抗氧化能力（Tota1antioxide capacity，T-AOC）及肝脏超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)及丙二醛(MDA)含量。Westem-Blot检测和免疫组化技术检测各组小鼠肝组织Bax、Bc1-2蛋白的表达。
结果：
1.在DICF模型中，与模型组比较，YLSPS各剂量组用能降低肝脏指数和脾脏指数；可降低血清ALT、AST、ALP、TBIL水平和肝组织MDA含量；降低血清中TNF-α与IL-1β；提高肝组织SOD、CAT、GSH-Px活性（P<0.05）；病理切片结果表明YLSPS各剂量组能够不同程度地减轻肝细胞的损伤程度。YLSPS能降低Bax mRNA的表达；增加肝组Bcl-2mRNA的表达(P<0.05)。
2.在NIM模型中，与模型组比较，YLSPS各剂量组能降低肝脏指数和脾脏指数；可降低血清ALT、AST、ALP和肝组织MDA含量；降低血清TNF-α与IL-6；提高血清T-AOC水平和肝组织SOD、GSX-Px活性（P<0.05）；病理切片结果表明YLSPS各组能够不同程度地减轻肝细胞的损伤程度。YLSPS能降低Bax蛋白表达；增加肝组织Bcl-2蛋白表达(P<0.05)。
3.在IBU模型中，与模型组比较，YLSPS各剂量组能降低肝脏指数和脾脏指数；可降低血清ALT、AST、ALP和肝组织MDA含量；提高血清T-AOC水平和肝组织SOD、GSX-Px活性（P<0.05）；病理切片结果表明YLSPS各组能够不同程度地减轻肝细胞的损伤程度。YLSPS能降低Bax蛋白表达；增加肝组织Bcl-2蛋白表达(P<0.05)。
结论：
YLSPS对双氯芬酸钠、尼美舒利和布洛芬所致小鼠肝损伤具有保护作用，其机制可能与其抗氧自由基、抑制脂质过氧化、抑制细胞凋亡作用有关。
Objective： To observe the protective effect of Yulangsan Polysaecharide(YLSPS) on diclofenac sodium，nimesulide and ibuprofen-induced liver injuryin Kunming mice.
Method：
1.Animal and treatment
Kunming mice were randomly divided into NC group，liver injured modelgroup with， high-，middle-，low-YLSPS group (600，300，150mg/kg) anddimethyl diphenyl bicarboxylate (200mg/kg DDB) group. The treatment groupswere orally administered once per day，whereas the normal and model groupswere orally administered with saline. Except normal mice, all the other micewere treated with drug induced liver injury for10days (nimesulide),14days(diclofenac, ibuprofen). At the end of the experimental period the mice were sacrificed and blood, liver samples were obtained.
2.The indexs of the liver and spleen were observed
3.Hematoxylineosin (HE) stain was used to examine the degree of hepaticinjury.
4.Diclofenac sodium model：Estimation of ALT，AST and ALP, the content ofTBIL, TNF-α and IL-1β in serum and the activities of SOD, GSH–Px and CAT，the content of MDA in liver tissue. The levels of expression of Bax and Bcl-2mRNA in liver were examined by Real-time quantitative-PCR.
5. Nimesulide model：Estimation of ALT，AST, ALP and T-AOC，the contentof TNF-α，IL-6in serum；the activities of SOD，GSH–Px and the content ofMDA in liver tissue. The expressions of Bax and Bcl-2in liver were detected byWestern Blot.
6.Ibuprofen model：Estimation of of ALT，AST and ALP，the content ofT-AOC in serum；the activities of SOD，GSH-Px and the content of MDA inliver tissue were investigated. The expressions of Bax and Bcl-2in liver weredetected by immunohistochemical and Western Blot.
Results：
1.Diclofenac model： Compared with model group, YLSPS could obviouslyreduce the weight of the liver and spleen. The activities of ALT，AST andALP，the content of TBIL，MDA，TNF-α and IL-1β and the expression ofBax could be decreased. The activities of SOD，GSH-Px，CAT and theexpression of Bcl-2could be increased (P<0.05), and the degree of hepaticinjury could be lessened.
2.Nimesulide model：Compared with model group， YLSPS could obviouslyreduce the activities of ALT，AST and ALP，the content of MDA，TNF-α， IL-6the index of liver, spleen and the expression of Bax. The activities ofSOD，GSH-Px，T-AOC and the expression of Bcl-2could be increased(P<0.05)；the degree of hepatic injury could be lessened.3.Ibuprofen model：Compared with model group，YLSPS could be decreasedthe index of liver and spleen，the activities of ALT，AST and ALP，the contentof MDA and the expression of Bax. The activities of SOD，GSH-Px，T-AOCand the expression of Bcl-2could be increased (P<0.05); the degree of hepaticinjury could be lessened.
Conclusion：
YLSPS has protective effect on diclofenac sodium, nimesulide andibuprofen-induced liver injury in mice. The mechanism may be related toattenuating free radical and inhibiting the effect on lipid peroxidation andapoptosis.
引文
1. Aithal GP. Hepatotoxicity related to antirheumatic drugs [J]. Nat RevRheumatol,2011；7(3)：139-50.
2. García Rodríguez LA，Pérez Gutthann S，Walker AM, et al. The role ofnon-steroidal anti-inflammatory drugs in acute liver injury[J]. BMJ,1992；305(6858)：865–868.
3. Kaplowit ZN. Mechanism of liver cell injury. J Hepatol,2000;32(1Suppl):39-47.
4. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
5. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury throughmitochondrial dysfunction: mechanisms and detection during preclinicalsafety studies. Fundam Clin Pharmacol.2008Aug;22(4):335-53.
6. Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis.1996;16(4):357-367.
7. Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due tomitochondrial dysfunction. Cell Biol Toxicol.1999;15(6):367-73.
8. Russmann S，Kullak-Ublick GA，Grattagliano I. Current Concepts ofMechanisms in Drug-Induced Hepatotoxicity [J]. Curr Med Chem2009；16(23)：3041-53.
9. Triebskorn R, Casper H, Heyd A, et al. Toxic effects of the non-steroidalanti-inflammatory drug diclofenac Part II. Cytological effects in liver,kidney, gills and intestine of rainbow trout (Oncorhynchus mykiss)[J].Aquat Toxicol2004；68(2)：151-166.
10.Walker AM. Quantitative studies of the risk of serious hepatic injury inpersons using nonsteroidal anti-inflammatory drugs[J]. Arthritis Rheum1997；40:201-208.
11.William ML， Drug-Induced Hepatotoxicity [J]. The New EnglandJournal of Medicine2003；349：474-85.
12.Baravalia Y, Vaghasiya Y, Chanda S. Hepatoprotective effect ofWoodfordia fruticosa Kurz flowers on diclofenac sodium induced livertoxicity in rats. Asian Pac J Trop Med,2011;4(5):342-6.
13.Cantoni L, Valaperta R, Ponsoda X, et al. Induction of hepatic hemeoxygenase-1by diclofenac in rodents: role of oxidative stress andcytochrome P450activity. Journal of Hepatology,2003;38(6):776-83.
14.Chung H，Kim HJ，Jang KS, et al. Comprehensive analysis of differentialgene expression profiles on diclofenac-induced acute mouse liver injuryand recovery [J]. Toxicol Lett2006；166(1)：77-87.
15.Oviedo-Gómez DG, Galar-Martínez M, García-Medina S, et al.Diclofenac-enriched artificial sediment induces oxidative stress inHyalella azteca。Environmental Toxicology and Pharmacology29(1):39–43.
16.Gülsen KN. Histopathologic Changes in Liver and Renal Tissues Inducedby Different Doses of Diclofenac Sodium in Rats [J]。Turk J Vet Anim Sci272003；5(27)：1131-1140.
17.Lauer B, Tuschl G, Kling M, et al. Species-specific toxicity of diclofenacand troglitazone in primary human and rat hepatocytes. Chem BiolInteract,2009;179(1):17-24.
18.Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeabilitytransition in diclofenac-induced hepatocyte injury in rats. Hepatology,2002;35(3):544-51.
19.Moorthy M，Fakurazi S and Ithnin H. The Histomorphological Analysisof Liver Following Administration of Low Doses of Diclofenac andIbuprofen [J]. Journal of Biological Sciences2009；9(7)：676-681.
20.Mueller D, Müller-Vieira U, Biemel KM, et al. Biotransformation ofdiclofenac and effects on the metabolome of primary human hepatocytesupon repeated dose exposure. Eur J Pharm Sci.2012Apr11;45(5):716-24.
21.Pohl LR，Martin JL，Hargus SJ. Immunochemical methods of studyingthe mechanism of diclofenac-induced hepatitis [J]. Arthritis Rheum1994；37:1557.
22.Pourahmad J, Mortada Y, Eskandari MR, et al. Involvement of LysosomalLabilisation and Lysosomal/mitochondrial Cross-Talk in DiclofenacInduced Hepatotoxicity. Iran J Pharm Res,2011;10(4):877-87.
23.Schapira D, Bassan L, Nahir A.M, et al. Diclofenac-inducedhepatotoxicity. Postgrad Med J,1986;62(723):63–65.
24.Shen S, Marchick MR, Davis MR, et al. Metabolic activation ofdiclofenac by human cytochrome P4503A4: role of5-hydroxydiclofenac.Chem Res Toxicol,1999;12(2):214-22.
25.Siu WP， Pun PB， Latchoumycandane C, et al. Bax-mediatedmitochondrial outer membrane permeabilization (MOMP)，distinct fromthe mitochondrial permeability transition， is a key mechanism indiclofenac-induced hepatocyte injury： Multiple protective roles ofcyclosporin A [J]. Toxicol Appl Pharmacol2008；227(3)：451-61.
26.Tomic Z, Milijasevic B, Sabo A, et al. Diclofenac and ketoprofen livertoxicity in rat. Eur J Drug Metab Pharmacokinet.2008;33(4):253-60.
27.Yano A，Higuchi S，Tsuneyama K, et al. Involvement of immune-relatedfactors in diclofenac-induced acute liver injury in mice[J]. Toxicology2012；293(1-3)：107-14.
28.Vanleeuwen JS，Vredenburg G，Dragovic S, et al. Metabolism relatedtoxicity of diclofenac in yeast as model system [J]。Toxicol Lett2011；200(3)：162-8.
29.Vickers AE. Tissue slices for the evaluation of metabolism-based toxicitywith the example of diclofenac. Chem Biol Interact,2009;179(1):9-16.
30.陈健，黄媛恒，王乃平，等.玉郎伞多糖和皂苷对氧自由基清除作用研究[J].中药药理与临床2007；23(5)：100.
31.段小群,焦杨,张士军,卢曦,等.玉郎伞多糖对肝星状细胞增殖和l型胶原合成的影响[J].中国现代医学杂志,2008,18(4):423-425.
32.付书婕.玉郎伞多糖对小鼠肝损伤的作用及其机制研究.南宁：广西医科大学.2008.
33.方允中,郑荣梁.自由基生物学的理论与应用[M].北京:科学出版社,2002，13-15.
34.付书婕，黄建春，王乃平，等.玉郎伞多糖对小鼠急性酒精性肝损伤保护作用的研究[J].中国药房2009；20(6)：406.
35.广西壮族自治区卫生厅.广西中药材标准［S］南宁：广西科学技术出版社1990：166.
36.黄仁彬，段小群，焦杨等.玉郎伞提取物对小鼠急性化学性肝损伤保护作用及其机制的研究[J].广西医科大学学报2003；20(6)：874.
37.黄仁彬,段小群,焦阳,等.玉郎伞提取物对小鼠化学性损伤保护作用及其机制的研究[J].广西医科大学学报,2003,22(6):874-875.
38.Kem MC. Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet,2000;355(204):591-592.
39.Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-Tcells from diclofenac-immunized mice against cultured syngeneichepatocytes exposed to diclofenac. Hepatology,1995;22(1):213-22.
40.Roberts RA, Ganey PE, Cynthia Ju., et al. Role of the kupffer cell inmediating hepatic toxicity and carcinogensis. Toxic Sci,2006;96(1):2-15.
41.Tiegs G. Experimental hepatitis and role of cytokines. Acta GastroenterolBelg,1997;60(2):176-179.
42.Adams JM, Cory S. Life or death decisions by the Bcl-2protein family.Trends Biochem Sic,2001;26(1):61-66.
43.Delft MF, Huang DC. How the Bcl-2family of proteins interact toregulate apoptosis. Cell Res,2006;16(2):203-213.
44.Goga LM, Vasiliu OM, Ionescu CR. Molecular mechanisms of apoptosis.Fas and TNF systems. ICE protease system Bcl-2family. Rev Med ChirSoc Med Nat Iasi,2001;105(1):23-29.
45.Grattagliano I, Portincasa P, Palmieri VO, et al. Overview on themechanisms of drug-induced liver cell death. Ann Hepatol.2002Oct-Dec;1(4):162-8.
46.Mizuhara H, Uno M, Seki Y. Critical involvement of interferon gamma inthe pathogenesis of T-cell activation-associated hepatitis and regulatorymechanisms of interleukin-6for the manifestations of hepatitis.Hepatology,1996;23(6):1608-1615.
47.倪峰.免疫活性的中药多糖.福建中医学院学报,2001;11(1):57.
48.徐叔云，卞如濂，陈修.药理实验方法学（第三版），北京：人民卫生出版社.2002；227-228.
1. García Rodríguez LA, Williams R, Derby LE, et al. Acute liver injuryassociated with nonsteroidal anti-inflammatory drugs and the role of riskfactors. Arch Intern Med,1994;154(3):311-6.
2. Gatti S, Bertazzoli M. Evaluation of isolated case reports onhepatotoxicity. Eur J Clin Pharmacol2002.57:919–920.
3. Grattagliano I, Portincasa P, Palmieri VO, et al. Overview on themechanisms of drug-induced liver cell death. Ann Hepatol.2002Oct-Dec;1(4):162-8.
4. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury throughmitochondrial dysfunction: mechanisms and detection during preclinicalsafety studies. Fundam Clin Pharmacol.2008Aug;22(4):335-53.
5. Betrosian AP, Flevari K, Andrianakis I, et al. Severe hemolytic anemiaand fatal hepatic failure associated with nimesulide. Dig Liver Dis.2009;41(1):80.
6. Berson A, Cazanave S, Descatoire V, et al. The anti-inflammatory drug,nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouplesmitochondria and induces mitochondrial permeability transition in humanhepatoma cells: protection by albumin. J Pharmacol Exp Ther,2006;318(1):444-54.
7. Chatterjee M, Sil PC. Protective role of Phyllanthus niruri againstnimesulide induced hepatic damage. Indian J Clin Biochem,2007;22(1):109-16.
8. Licata A, Calvaruso V, Cappello M, et al. Clinical course and outcomes ofdrug-induced liver injury: Nimesulide as the first implicated medication[J]. Dig Liver Dis2010Feb;42(2):143-8.
9. Merlani G, Fox M, Oehen HP, et al. Fatal hepatoxicity secondary tonimesulide [J]. Eur J Clin Pharmacol2001;57(4):321-6.
10.Mingatto FE, Rodrigues T, Pigoso AA, et al. The critical role ofmitochondrial energetic impairment in the toxicity of nimesulide tohepatocytes. J Pharmacol Exp Ther,2002;303(2):601-7.
11.Monteiro JP, Martins AF, Lúcio M, et al. Nimesulide interaction withmembrane model systems: Are membrane physical effects involved innimesulide mitochondrial toxicity?[J]. Toxicol In Vitro2011;25(6):1215-23.
12.Rainsford KD. An analysis from clinico-epidemiological data of theprincipal adverse events from the COX-2selective NSAID, nimesulide,with particular reference to hepatic injury. Inflammopharmacology,1998;6(3):203-21.
13.Sbeit W, Krivoy N, Shiller M, et al. Nimesulide-induce acute hepatitis.Ann Pharmacother2001;35(9):1049-52.
14.Schattner A, Sokolovskaya JC. Fatal hepatitis and renal failure duringtreatment with nimesulide. Journal of Internal Medicine2000,247,153–155.
15.Singh BK, Tripathi M, Pandey PK, et al. Nimesulide aggravates redoximbalance and calcium dependent mitochondrial permeability transitionleading to dysfunction in vitro. Toxicology2010.275,1–9.
16.Tan HH, Ong WMC, Lai SH, et al. Nimesulide-induced hepatotoxicityand fatal hepatic failure. Singapore Med2007;48(6):582.
17.Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicityassociated with nimesulide and other non-steroidal anti-inflammatorydrugs. BMJ2003;327(7405):18-22.
18.陈健，黄媛恒，王乃平，等.玉郎伞多糖和皂苷对氧自由基清除作用研究[J].中药药理与临床,2007,23(5).
19.段小群,焦杨,张士军,等.玉郎伞多糖对肝星状细胞增殖和l型胶原合成的影响[J].中国现代医学杂志,2008,18(4):423-425.
20.方允中,郑荣梁.自由基生物学的理论与应用[M].北京:科学出版社,2002，13-15.
21.付书婕，王乃平，黄仁彬.植物多糖免疫调节作用的研究进展.《时珍国医国药》2008;19(1):99-101.
22.付书婕.玉郎伞多糖对小鼠肝损伤的作用及其机制研究.南宁：广西医科大学.2008.
23.黄仁彬,段小群,焦阳,等.玉郎伞提取物对小鼠化学性损伤保护作用及其机制的研究[J].广西医科大学学报,2003,22(6):874-875.
24.黄必义,黄仁彬,卢曦,等.玉郎伞多糖对肝星状细胞氧应激脂质过氧化作用的影响[J].时珍国医国药,2008,19(4):814-815.
25.Adamson GM, Billings RE. Tumor necrosis factor induced oxidativestress in isolated mouse hepatocytes. Arch Biochem Biophys,1992;294(1):223-229.
26.藏国庆，周霞秋，俞红，等.肿瘤坏死因子2α诱导肝细胞凋亡在暴发性肝衰竭中的作用.中华消化杂志,2000;20(3):163.
27.Kem MC. Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet,2000;355(204):591-592.
28.Mizuhara H, Uno M, Seki Y. Critical involvement of interferon gamma inthe pathogenesis of T-cell activation-associated hepatitis and regulatorymechanisms of interleukin-6for the manifestations of hepatitis.Hepatology,1996;23(6):1608-1615.
29.Pauli U. Porcine TNF: a review. Vet Immunol Immunopathol,1995;47(3-4):187-201.
30.Sheu SS, Nauduri D, Anders MW. Targeting antioxidants tomitochondria:a therapeutic direction. Biochimica et Biophysica Acta20061762,256–265.
31.Tiegs G, Kusters S, Kunstle G, et al. Ebselen protects mice against T-celldependent TNF-mediated apoptotic liver injury, Journal of Pharmacologyand Experimental Therapeutics,1998;287(3):1098-1104.
32.Tiegs G. Experimental hepatitis and role of cytokines. Acta GastroenterolBelg,1997;60(2):176-179.
33.Adams JM, Cory S. Life or death decisions by the Bcl-2protein family.Trends Biochem Sic,2001;26(1):61-66.
34.Delft MF, Huang DC. How the Bcl-2family of proteins interact toregulate apoptosis. Cell Res,2006;16(2):203-213.
35.Goga LM, Vasiliu OM, Ionescu CR. Molecular mechanisms of apoptosis.Fas and TNF systems ICE protease system. Bcl-2family. Rev Med ChirSoc Med Nat Iasi,2001;105(1):23-29.
36.Greenwald RA.1985. CRC Handbook of Methods for Oxygen RadicalResearch.1st Edn., CRC Press, Boca Raton, Florida, ISBN:0849329361,pp:447.
37.Han YH, Kim SH, Kim H, et al. Intracellular GSH levels rather than ROSlevels are tightly related to AMA induced HeLa cell death.Chemico-Biological Interactions2008.171,67–78.
38.Kaplowit ZN. Mechanism of liver cell injury. J Hepatol，2000;32(1Suppl):39-47.
39.Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
40.Kukhta VK, Marozkina NV, Sokolchik IG, et al. Molecular mechanismsof apoptosis. Ukr Biokhim Zh,2003;75(6):5-9.
41.李勇，孔令青，高洪，等.自由基与疾病研究进展.动物医学进展，2008；29（4）：85-87.
42.Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis.1996;16(4):357-367.
43.Machy TJ, Borkowski A, Amin, et al. Bc1-2/Bax ratio as a predictivemarker for the rapeutic response to radiotherapy in patients with prostatecancer. Urologe,1998;56(2):1085.
44.Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat RevMol Cell Biol,2001;2(1):63-7.
45.Orrenius S. Reactive oxygen species in mitochondria-mediated cell death.Drug Metabolism Reviews2007，39,443–455.
46.Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due tomitochondrial dysfunction. Cell Biol Toxicol.1999;15(6):367-73.
47.Sastre J, Serviddio G, Pereda J, et al. Mitochondrial function in liverdisease. Front Biosci,2007;12:1200-9.
48.Tripathi M, Singh BK, Raisuddin S, et al. Abrogation of nimesulideinduced oxidative stress and mitochondria mediated apoptosis by Fumariaparviflora Lam. extract. J Ethnopharmacol,2011;136(1):94-102.
49.William ML. Drug-Induced Hepatotoxicity [J]. The New EnglandJournal of Medicine2003;349:474-85.
50.徐叔云，卞如濂，陈修.药理实验方法学（第三版），北京：人民卫生出版社.2002；227-228.
1. Aithal GP. Hepatotoxicity related to antirheumatic drugs [J]. Nat RevRheumatol,2011；7(3)：139-50.
2. García Rodríguez LA, Williams R, Derby LE, et al. Acute liver injuryassociated with nonsteroidal anti-inflammatory drugs and the role of riskfactors. Arch Intern Med,1994;154(3):311-6.
3. García Rodríguez LA，Pérez Gutthann S，Walker AM, et al. The role ofnon-steroidal anti-inflammatory drugs in acute liver injury [J]。BMJ1992；305(6858)：865–868.
4. Grattagliano I，Portincasa P，Palmieri VO, et al. Overview on themechanisms of drug-induced liver cell death。Ann Hepatol2002；1(4)：162-8.
5. Lapeyre-Mestre M, de Castro AM, Bareille MP, et al. Non-steroidalanti-inflammatory drug-related hepatic damage in France and Spain:analysis from national spontaneous reporting systems. Fundam ClinPharmacol,2006;20(4):391-5.
6. Michael PH，Cynthia J. Mechanisms of Drug-Induced Liver Injury.AAPS J2006；8(1)：48–54.
7. O'Connor N, Dargan PI, Jones AL. Hepatocellular damage fromnon-steroidal anti-inflammatory drugs. QJM,2003;96(11):787-91.
8. Walker AM. Quantitative studies of the risk of serious hepatic injury inpersons using nonsteroidal anti-inflammatory drugs[J]。Arthritis Rheum1997；40:201-208.
9. William ML. Drug-Induced Hepatotoxicity [J]. The New England Journalof Medicine2003；349：474-85.
10.Bennett WE，Turmelle YP，Shepherd RW. Ibuprofen-Induced Liver Injuryin an Adolescent Athlete。ClinPediatr (Phila)2009；48(1)：84-6.
11.Cazanave S, Vadrot N, Tinel M, et al. Ibuprofen administration attenuatesserum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosisand mouse mortality after Fas stimulation. Toxicol Appl Pharmacol,2008;231(3):336-43.
12.Ilic S，Drmic D，Zarkovic K，et al. Ibuprofen hepatic encephalopathy，hepatomegaly，gastric lesion and gastric pentadecapeptide BPC157inrats [J]. Eur J Pharmacol2011；667(1-3)：322-9.
13.Mahalakshmi R, Rajesh P, Ramesh N, et al. Hepatoprotective Activity onVitex negundo Linn.(Verbenaceae) by using Wistar Albino Rats inIbuprofen Induced Model. International Journal of Pharmacology,2010,6:658-663.
14.Moorthy M，Fakurazi S and Ithnin H. The Histomorphological Analysisof Liver Following Administration of Low Doses of Diclofenac andIbuprofen [J]. Journal of Biological Sciences2009；9(7)：676-681.
15.Mu oz-García A. Ibuprofen-associated hepatotoxicity: Analysis of caseseries included in the Spanish DILI registry. Journal of Hepatology2011；54：206.
16.Rainsford KD. Ibuprofen: pharmacology， efficacy and safety.Inflammopharmacology2009；17(6)：275-342.
17.王淑英,倪国栋.布洛芬致急性重症肝炎1例[J].中国临床药学杂志2000；9(5)：316.
18.陈健,黄媛恒,王乃平,等.玉郎伞多糖和皂苷对氧自由基清除作用研究[J]。中药药理与临床2007；23(5)：100.
19.段小群,焦杨,张士军,等.玉郎伞多糖对肝星状细胞增殖和l型胶原合成的影响[J].中国现代医学杂志,2008,18(4):423-425.
20.广西壮族自治区卫生厅.广西中药材标准［S］南宁：广西科学技术出版社，1990：166.
21.付书婕，黄建春，王乃平，等.玉郎伞多糖对小鼠急性酒精性肝损伤保护作用的研究[J].中国药房2009；20(6)：406.
22.黄仁彬，段小群，焦杨等.玉郎伞提取物对小鼠急性化学性肝损伤保护作用及其机制的研究[J]。广西医科大学学报2003；20(6)：874.
23.黄必义,黄仁彬,卢曦,等.玉郎伞多糖对肝星状细胞氧应激脂质过氧化作用的影响[J].时珍国医国药,2008,19(4):814-815.
24.付书婕.玉郎伞多糖对小鼠肝损伤的作用及其机制研究.南宁：广西医科大学.2008.
25.黄正明，杨新波，曹文斌，等.化学性及免疫性肝损伤模型的方法学研究.解放军药学学报，2005；21（1）：33-38.
26.Adamson GM, Billings RE. Tumor necrosis factor induced oxidativestress in isolated mouse hepatocytes. Arch Biochem Biophys,1992;294(1):223-229.
27.方允中,郑荣梁.自由基生物学的理论与应用[M].北京:科学出版社,2002，13-15.
28.李勇，孔令青，高洪，等.自由基与疾病研究进展.动物医学进展，2008；29（4）：85-87.
29.Kem MC. Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet,2000;355(204):591-592.
30.Tiegs G. Experimental hepatitis and role of cytokines. Acta GastroenterolBelg,1997;60(2):176-179.
31.张晓静,刘会东.植物多糖提取分离及药理作用的研究进展〔J〕.时珍国医国药.2(X)3,14(8):495-497。
32.Adams JM, Cory S. Life or death decisions by the Bcl-2protein family.Trends Biochem Sic,2001;26(1):61-66.
33.Delft MF, Huang DC. How the Bcl-2family of proteins interact toregulate apoptosis. Cell Res,2006;16(2):203-213.
34.Goga LM, Vasiliu OM, Ionescu CR. Molecular mechanisms of apoptosis.Fas and TNF systems. ICE protease system. Bcl-2family. Rev Med ChirSoc Med Nat Iasi,2001;105(1):23-29.
35.Kaplowit ZN. Mechanism of liver cell injury. J Hepatol,2000;32(1Suppl):39-47.
36.Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
37.Kukhta VK, Marozkina NV, Sokolchik IG, et al. Molecular mechanismsof apoptosis. Ukr Biokhim Zh,2003;75(6):5-9.
38.Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury throughmitochondrial dysfunction: mechanisms and detection during preclinicalsafety studies. Fundam Clin Pharmacol.2008Aug;22(4):335-53.
39.Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis.1996;16(4):357-367.
40.Machy TJ, Borkowski A, Amin, et al. Bc1-2/Bax ratio as a predictivemarker for the rapeutic response to radiotherapy in patients with prostatecancer. Urologe,1998;56(2):1085.
41.Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due tomitochondrial dysfunction. Cell Biol Toxicol.1999;15(6):367-73.
42.Rekka E, Ayalogu EO, Lewis DF, et al. Induction of hepatic microsomalCYP4A activity and of peroxisomal beta-oxidation by two non-steroidalanti-inflammatory drugs. Arch Toxicol.1994;68(2):73-8.
43.Sastre J, Serviddio G, Pereda J, et al. Mitochondrial function in liverdisease. Front Biosci,2007;12:1200-9.
44.汤新慧，高静.实验性肝损伤的损伤机制.中西医结合肝病杂志,2002；12（1）：53-55.
45.徐叔云，卞如濂，陈修.药理实验方法学（第三版），北京：人民卫生出版社.2002；227-228.
1. Aithal GP. Hepatotoxicity related to antirheumatic drugs [J]. Nat RevRheumatol,2011；7(3)：139-50.
2. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition andphenotype standardization in drug-induced liver injury (DILI). ClinPharmacol Ther2011.
3. Andrade RJ, Robles M, Fernandez-Castaner A, et al. Assessment ofdrug-induced hepatotoxicity in clinical practice: a challenge forgas-troenterologists[J]. World J Gastroenterol,2007,13(3):329.
4.白汉玉．药源性肝损害［J］．中级医刊，1994，29(2):11-13．
5. Betrosian AP, Flevari K, Andrianakis I, et al. Severe hemolytic anemiaand fatal hepatic failure associated with nimesulide. Dig Liver Dis.2009;41(1):80.
6. Berson A, Cazanave S, Descatoire V, et al. The anti-inflammatory drug,nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouplesmitochondria and induces mitochondrial permeability transition inhuman hepatoma cells: protection by albumin. J Pharmacol Exp Ther,2006;318(1):444-54.
7. Buratti S, Lavine JE. Drugs and the liver:advances in metadbolism,toxicity, and the rapeutics[J].Curr Opin Pediatr,2002,14(5):601.
8. Cantoni L, Valaperta R, Ponsoda X, et al. Induction of hepatic hemeoxygenase-1by diclofenac in rodents: role of oxidative stress andcytochrome P450activity. Journal of Hepatology,2003;38(6):776-83.
9. Cazanave S, Vadrot N, Tinel M, et al. Ibuprofen administrationattenuates serum TNF-alpha levels, hepatic glutathione depletion,hepatic apoptosis and mouse mortality after Fas stimulation. ToxicolAppl Pharmacol,2008;231(3):336-43.
10.陈成伟.药物与中毒性肝病.第一版.上海科学技术出版社.2002,4-5.
11.陈一凡，蔡皓东．中药引起肝损害的调查分析［J］．药物不良反应杂志，1999，1(1)：27-32．
12.García Rodríguez LA，Pérez Gutthann S，Walker AM, et al. The roleof non-steroidal anti-inflammatory drugs in acute liver injury[J]. BMJ,1992；305(6858)：865–868.
13.侯鹏鹏,药物性肝炎研究进展,[J]医学理论与实践2008;8(21):899-890.
14.Ilic S，Drmic D，Zarkovic K，et al. Ibuprofen hepatic encephalopathy，hepatomegaly，gastric lesion and gastric pentadecapeptide BPC157inrats [J]. Eur J Pharmacol2011；667(1-3)：322-9.
15.贾继东,崔儒涛.非甾体抗炎药的肝脏毒性[J].肝脏,2001,6(1):50.
16.Kaplowit ZN. Mechanism of liver cell injury. J Hepatol,2000;32(1Suppl):39-47.
17.Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
18.李慧敏,赵叶丽.药物性肝炎65例临床分析[J].浙江中西医结合杂志,2003,13(3):169-170.
19.厉有名.药物性肝损害的临床类型及诊断策略.中华肝脏病杂志,2004,12:445-446.
20.Losser MR, Payen D. Mechanisms of liver damage. Semin LiverDis.1996;16(4):357-367.
21.陆玮婷，李军，欧宁，等．72例中药引起药物性肝损的临床研究［J］．江苏医药，2007，33(6)：546-547．
22.Malcolm A, Steele MD. Toxic hepatitis with isoniazid and rifampin ameta-analysis[J]. Chest,1999,2:465~471.
23.Maria VA, Victtorino RM. Development and validation of a clinicalscale for the diagnosis of drug-induced hepatitis.Hepatology,1997,26:664-669.
24.Masubuchi Y, Nakayama S, Horie T. Role of mitochondrialpermeability transition in diclofenac-induced hepatocyte injury in rats.Hepatology,2002;35(3):544-51.
25.Merlani G, Fox M, Oehen HP, et al. Fatal hepatoxicity secondary tonimesulide [J]. Eur J Clin Pharmacol2001;57(4):321-6.
26.Mingatto FE, Rodrigues T, Pigoso AA, et al. The critical role ofmitochondrial energetic impairment in the toxicity of nimesulide tohepatocytes. J Pharmacol Exp Ther,2002;303(2):601-7.
27.Monteiro JP, Marti ns AF, Lúcio M, et al. Nimesulide interaction withmembrane model systems: Are membrane physical effects involved innimesulide mitochondrial toxicity?[J]. Toxicol In Vitro2011;25(6):1215-23.
28.Mu oz-García A. Ibuprofen-associated hepatotoxicity: Analysis ofcase series included in the Spanish DILI registry. Journal ofHepatology2011；54：206.
29.茅益民,曾民德.药品评价.2007;4(6):389.
30.钱又宏,姚光弼.药物性肝病的病因和临床表现43例分析[J].肝脏,2000,1(3):166-169.
31.Roberts RA, Ganey PE, Cynthia Ju, et al. Role of the kupffer cell inmediating hepatic toxicity and carcinogensis. Toxic Sci,2006;96(1):2-15.
32.Robin MA, LeRoy M, Descatoire V, et al. Plasma membranecytochromes P450s neoantigens and autoinunune targets indrug-induced hepatitis[J]. J Hepatol,1997,26(suppl1):23.
33.宋建华．药物性肝病40例临床分析［J］．药学服务与研究，2005，5(3)：282．
34.Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injuryin Japan: an analysis of1676cases between1997and
2006.Hepatology Res2009;39:427-31.
35.杨冰华，张轶停，张春艳，等．药物性肝损害［J］．临床和实验医学杂志，2003，2(1)：62-64．
36.姚光弼.重视中药和草药引起的肝损害.肝脏,2005,10(1):1.
37.袁海鹏，李廷青．药物性肝病的发病机制及治疗[J]．山东医药，2004，4(10)：54—55．
38.张涛，贾继东．107例药物性肝损害的病因和临床特点［J］．肝脏，2005，10(3)：174-176．
39.张惠芸.腺苷蛋氨酸治疗慢性肝炎及肝炎肝硬化的疗效[J]中国临床药学杂志,2000,9(6):335-338.
40.赵凤芹,王江滨.抗结核药物诱导肝损伤的评价[J].国外医学呼吸系统分册,2003,23(6):322-324.
41.周艳莉，杨毅恒．中成药致肝损害401例分析［J］．中国药物应用与监测，2007，4(4)：6-8．
42.王凡,刘宾,李莉,等.急性药物性肝损害的临床分析和治疗探讨[J].中国医院用药评价与分析,2007,7(3):193-195.
43.萬古直,张临详译.传统草药(“汉方药”)与药物性肝损害[J].日报医.
44.汪云,朱丽影.药物性肝炎的发病机制[J].黑龙江医学,2008,32(5):34;342.
45.王伟芳，陈一华．药物性肝损害及其预防［J］．临床肝胆病杂志，1993，9(3)：124-127．
46. Wang Z, Liang X, Yu J, et al. Non-genetic risk factors and predictingefficacy for docetaxel-drug-induced liver injury among metastatic breastcancer patients[J].J Gastroenterol Hepatol,2012,27(8):1348-1352.
47.Walker AM. Quantitative studies of the risk of serious hepatic injuryin persons using nonsteroidal anti-inflammatory drugs[J]. ArthritisRheum1997；40:201-208.
48.William ML. Drug-Induced Hepatotoxicity [J]. The New EnglandJournal of Medicine2003；349：474-85.
1.国家药典委员会.卫生部药品标准中药成方制剂.第十二册.1997:161.
2.蒋伟哲，孔晓龙，段小群，等.龙眼参对机体氧自由基清除作用的研究[J].中国药房，2011,12（8）：543-455.
3.荣延平，黄仁彬，陈晓宇,等.玉郎伞多糖提取工艺的正交法优化[J].时珍国医国药,2012，23(3):567-569.
4.黄仁斌，林兴，蒋伟哲，等.玉郎伞化学成分对自发性高血压大鼠血压的影响[J].中国医院药学杂志，2006,26（2）：130-132.
5.段小群，焦扬，黄仁斌，等.玉郎伞提取物对大鼠自发性高血压的影响[J].广西医科大学学报，2003,20（1）：18.
6.黄仁彬,吕纪华,张绪东,等.玉郎伞黄酮类化合物对大鼠离体心脏缺血再灌注损伤的作用[J].华西药学杂志,2010，25(3):287-289.
7.吕纪华,贺敏,黄建春,等.玉郎伞黄酮对心肌缺血再灌注损伤心肌组织ATP酶和凋亡蛋白的影响[J].中国实验方剂学杂志,2010，16(13):162-166.
8.李健玲,陈兆霓,吕纪华,等.玉郎伞皂苷对大鼠离体心脏缺血再灌注损伤的保护作用[J].中国实验方剂学杂志,2012，18(9):250-253.
9.陈丽,张士军,黄建春,等.玉郎伞提取物对高脂血症大鼠血液流变学的影响[J].华西药学杂志,2012，22：41-44.
10.陈丽,黄仁彬,张绪东,等.玉郎伞总黄酮对洛伐他汀降血脂的增效作用研究[J].中成药,2013，35(2):225-228.
11.覃斐章，简洁，焦杨，等.YLSC对心肌缺血再灌注损伤细胞ASK1、Cyt-C、Bcl-2、Bax蛋白表达的影响[J].山东医药,2012，52：39-41.
12.简洁,刘曦,黄仁彬，等.玉郎伞2种查尔酮单体对心肌过氧化损伤的保护作用研究[J].中国药房,2010，21：2124-2126.
13.简洁，黄仁彬.玉郎伞2，6-二甲氧基查尔酮含药血清对心肌细胞氧化损伤的影响[J].中国现代医学杂志,2011，21(15):1809-1813.
14.段小群,焦杨,张士军,等.玉郎伞多糖对肝星状细胞增殖和I型胶原合成的影响[J].中国现代医学杂志,2008，18(4):423-425.
15.梁颖娥，付书婕，贝学室.玉郎伞多糖解酒作用及机制研究[J].时珍国医国药,2011，22(11):2651-2652.
16.黄媛恒，陈健，黄仁彬,等.玉郎伞提取物对模型大鼠胸膜炎TNF-α、PGE2、NO的影响[J].中国药房,2010,21(3):200-202.
17.陈丽，张绪东，焦杨,等.玉郎伞提取物对食饵性高脂血症大鼠肝脏脂蛋白代谢相关酶活性及脂肪肝的影响[J].中国实验方剂学杂志,2012，18(9):254-258.
18.郭又嘉,文坎，张士军,等.玉郎伞皂苷对四氯化碳诱导大鼠肝纤维化的影响[J].中国药理学通报,2012，28(4):554-558.
19.文坎，郭又嘉，蒙明瑜,等.玉郎伞黄酮对四氯化碳诱导小鼠急性肝损伤的保护作用[J].中国实验方剂学杂志,2012，18(16):269-272.
20.郭又嘉，蒙明瑜，焦杨,等.玉郎伞黄酮对四氯化碳诱导的大鼠肝纤维化的影响[J].中国实验方剂学杂志,2012，18(16):198-202.
21.陈晓宇，荣延平，张士军,等.玉郎伞多糖对Aβ25-35诱导PC12细胞损伤的保护作用研究[J].中国药房,2013，24(19):1735-1737.
2. García Rodríguez LA，Pérez Gutthann S，Walker AM, et al. The role ofnon-steroidal anti-inflammatory drugs in acute liver injury[J]. BMJ,1992；305(6858)：865–868.
3. Kaplowit ZN. Mechanism of liver cell injury. J Hepatol,2000;32(1Suppl):39-47.
4. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
5. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury throughmitochondrial dysfunction: mechanisms and detection during preclinicalsafety studies. Fundam Clin Pharmacol.2008Aug;22(4):335-53.
6. Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis.1996;16(4):357-367.
7. Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due tomitochondrial dysfunction. Cell Biol Toxicol.1999;15(6):367-73.
8. Russmann S，Kullak-Ublick GA，Grattagliano I. Current Concepts ofMechanisms in Drug-Induced Hepatotoxicity [J]. Curr Med Chem2009；16(23)：3041-53.
9. Triebskorn R, Casper H, Heyd A, et al. Toxic effects of the non-steroidalanti-inflammatory drug diclofenac Part II. Cytological effects in liver,kidney, gills and intestine of rainbow trout (Oncorhynchus mykiss)[J].Aquat Toxicol2004；68(2)：151-166.
10.Walker AM. Quantitative studies of the risk of serious hepatic injury inpersons using nonsteroidal anti-inflammatory drugs[J]. Arthritis Rheum1997；40:201-208.
11.William ML， Drug-Induced Hepatotoxicity [J]. The New EnglandJournal of Medicine2003；349：474-85.
12.Baravalia Y, Vaghasiya Y, Chanda S. Hepatoprotective effect ofWoodfordia fruticosa Kurz flowers on diclofenac sodium induced livertoxicity in rats. Asian Pac J Trop Med,2011;4(5):342-6.
13.Cantoni L, Valaperta R, Ponsoda X, et al. Induction of hepatic hemeoxygenase-1by diclofenac in rodents: role of oxidative stress andcytochrome P450activity. Journal of Hepatology,2003;38(6):776-83.
14.Chung H，Kim HJ，Jang KS, et al. Comprehensive analysis of differentialgene expression profiles on diclofenac-induced acute mouse liver injuryand recovery [J]. Toxicol Lett2006；166(1)：77-87.
15.Oviedo-Gómez DG, Galar-Martínez M, García-Medina S, et al.Diclofenac-enriched artificial sediment induces oxidative stress inHyalella azteca。Environmental Toxicology and Pharmacology29(1):39–43.
16.Gülsen KN. Histopathologic Changes in Liver and Renal Tissues Inducedby Different Doses of Diclofenac Sodium in Rats [J]。Turk J Vet Anim Sci272003；5(27)：1131-1140.
17.Lauer B, Tuschl G, Kling M, et al. Species-specific toxicity of diclofenacand troglitazone in primary human and rat hepatocytes. Chem BiolInteract,2009;179(1):17-24.
18.Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeabilitytransition in diclofenac-induced hepatocyte injury in rats. Hepatology,2002;35(3):544-51.
19.Moorthy M，Fakurazi S and Ithnin H. The Histomorphological Analysisof Liver Following Administration of Low Doses of Diclofenac andIbuprofen [J]. Journal of Biological Sciences2009；9(7)：676-681.
20.Mueller D, Müller-Vieira U, Biemel KM, et al. Biotransformation ofdiclofenac and effects on the metabolome of primary human hepatocytesupon repeated dose exposure. Eur J Pharm Sci.2012Apr11;45(5):716-24.
21.Pohl LR，Martin JL，Hargus SJ. Immunochemical methods of studyingthe mechanism of diclofenac-induced hepatitis [J]. Arthritis Rheum1994；37:1557.
22.Pourahmad J, Mortada Y, Eskandari MR, et al. Involvement of LysosomalLabilisation and Lysosomal/mitochondrial Cross-Talk in DiclofenacInduced Hepatotoxicity. Iran J Pharm Res,2011;10(4):877-87.
23.Schapira D, Bassan L, Nahir A.M, et al. Diclofenac-inducedhepatotoxicity. Postgrad Med J,1986;62(723):63–65.
24.Shen S, Marchick MR, Davis MR, et al. Metabolic activation ofdiclofenac by human cytochrome P4503A4: role of5-hydroxydiclofenac.Chem Res Toxicol,1999;12(2):214-22.
25.Siu WP， Pun PB， Latchoumycandane C, et al. Bax-mediatedmitochondrial outer membrane permeabilization (MOMP)，distinct fromthe mitochondrial permeability transition， is a key mechanism indiclofenac-induced hepatocyte injury： Multiple protective roles ofcyclosporin A [J]. Toxicol Appl Pharmacol2008；227(3)：451-61.
26.Tomic Z, Milijasevic B, Sabo A, et al. Diclofenac and ketoprofen livertoxicity in rat. Eur J Drug Metab Pharmacokinet.2008;33(4):253-60.
27.Yano A，Higuchi S，Tsuneyama K, et al. Involvement of immune-relatedfactors in diclofenac-induced acute liver injury in mice[J]. Toxicology2012；293(1-3)：107-14.
28.Vanleeuwen JS，Vredenburg G，Dragovic S, et al. Metabolism relatedtoxicity of diclofenac in yeast as model system [J]。Toxicol Lett2011；200(3)：162-8.
29.Vickers AE. Tissue slices for the evaluation of metabolism-based toxicitywith the example of diclofenac. Chem Biol Interact,2009;179(1):9-16.
30.陈健，黄媛恒，王乃平，等.玉郎伞多糖和皂苷对氧自由基清除作用研究[J].中药药理与临床2007；23(5)：100.
31.段小群,焦杨,张士军,卢曦,等.玉郎伞多糖对肝星状细胞增殖和l型胶原合成的影响[J].中国现代医学杂志,2008,18(4):423-425.
32.付书婕.玉郎伞多糖对小鼠肝损伤的作用及其机制研究.南宁：广西医科大学.2008.
33.方允中,郑荣梁.自由基生物学的理论与应用[M].北京:科学出版社,2002，13-15.
34.付书婕，黄建春，王乃平，等.玉郎伞多糖对小鼠急性酒精性肝损伤保护作用的研究[J].中国药房2009；20(6)：406.
35.广西壮族自治区卫生厅.广西中药材标准［S］南宁：广西科学技术出版社1990：166.
36.黄仁彬，段小群，焦杨等.玉郎伞提取物对小鼠急性化学性肝损伤保护作用及其机制的研究[J].广西医科大学学报2003；20(6)：874.
37.黄仁彬,段小群,焦阳,等.玉郎伞提取物对小鼠化学性损伤保护作用及其机制的研究[J].广西医科大学学报,2003,22(6):874-875.
38.Kem MC. Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet,2000;355(204):591-592.
39.Kretz-Rommel A, Boelsterli UA. Cytotoxic activity of T cells and non-Tcells from diclofenac-immunized mice against cultured syngeneichepatocytes exposed to diclofenac. Hepatology,1995;22(1):213-22.
40.Roberts RA, Ganey PE, Cynthia Ju., et al. Role of the kupffer cell inmediating hepatic toxicity and carcinogensis. Toxic Sci,2006;96(1):2-15.
41.Tiegs G. Experimental hepatitis and role of cytokines. Acta GastroenterolBelg,1997;60(2):176-179.
42.Adams JM, Cory S. Life or death decisions by the Bcl-2protein family.Trends Biochem Sic,2001;26(1):61-66.
43.Delft MF, Huang DC. How the Bcl-2family of proteins interact toregulate apoptosis. Cell Res,2006;16(2):203-213.
44.Goga LM, Vasiliu OM, Ionescu CR. Molecular mechanisms of apoptosis.Fas and TNF systems. ICE protease system Bcl-2family. Rev Med ChirSoc Med Nat Iasi,2001;105(1):23-29.
45.Grattagliano I, Portincasa P, Palmieri VO, et al. Overview on themechanisms of drug-induced liver cell death. Ann Hepatol.2002Oct-Dec;1(4):162-8.
46.Mizuhara H, Uno M, Seki Y. Critical involvement of interferon gamma inthe pathogenesis of T-cell activation-associated hepatitis and regulatorymechanisms of interleukin-6for the manifestations of hepatitis.Hepatology,1996;23(6):1608-1615.
47.倪峰.免疫活性的中药多糖.福建中医学院学报,2001;11(1):57.
48.徐叔云，卞如濂，陈修.药理实验方法学（第三版），北京：人民卫生出版社.2002；227-228.
1. García Rodríguez LA, Williams R, Derby LE, et al. Acute liver injuryassociated with nonsteroidal anti-inflammatory drugs and the role of riskfactors. Arch Intern Med,1994;154(3):311-6.
2. Gatti S, Bertazzoli M. Evaluation of isolated case reports onhepatotoxicity. Eur J Clin Pharmacol2002.57:919–920.
3. Grattagliano I, Portincasa P, Palmieri VO, et al. Overview on themechanisms of drug-induced liver cell death. Ann Hepatol.2002Oct-Dec;1(4):162-8.
4. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury throughmitochondrial dysfunction: mechanisms and detection during preclinicalsafety studies. Fundam Clin Pharmacol.2008Aug;22(4):335-53.
5. Betrosian AP, Flevari K, Andrianakis I, et al. Severe hemolytic anemiaand fatal hepatic failure associated with nimesulide. Dig Liver Dis.2009;41(1):80.
6. Berson A, Cazanave S, Descatoire V, et al. The anti-inflammatory drug,nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouplesmitochondria and induces mitochondrial permeability transition in humanhepatoma cells: protection by albumin. J Pharmacol Exp Ther,2006;318(1):444-54.
7. Chatterjee M, Sil PC. Protective role of Phyllanthus niruri againstnimesulide induced hepatic damage. Indian J Clin Biochem,2007;22(1):109-16.
8. Licata A, Calvaruso V, Cappello M, et al. Clinical course and outcomes ofdrug-induced liver injury: Nimesulide as the first implicated medication[J]. Dig Liver Dis2010Feb;42(2):143-8.
9. Merlani G, Fox M, Oehen HP, et al. Fatal hepatoxicity secondary tonimesulide [J]. Eur J Clin Pharmacol2001;57(4):321-6.
10.Mingatto FE, Rodrigues T, Pigoso AA, et al. The critical role ofmitochondrial energetic impairment in the toxicity of nimesulide tohepatocytes. J Pharmacol Exp Ther,2002;303(2):601-7.
11.Monteiro JP, Martins AF, Lúcio M, et al. Nimesulide interaction withmembrane model systems: Are membrane physical effects involved innimesulide mitochondrial toxicity?[J]. Toxicol In Vitro2011;25(6):1215-23.
12.Rainsford KD. An analysis from clinico-epidemiological data of theprincipal adverse events from the COX-2selective NSAID, nimesulide,with particular reference to hepatic injury. Inflammopharmacology,1998;6(3):203-21.
13.Sbeit W, Krivoy N, Shiller M, et al. Nimesulide-induce acute hepatitis.Ann Pharmacother2001;35(9):1049-52.
14.Schattner A, Sokolovskaya JC. Fatal hepatitis and renal failure duringtreatment with nimesulide. Journal of Internal Medicine2000,247,153–155.
15.Singh BK, Tripathi M, Pandey PK, et al. Nimesulide aggravates redoximbalance and calcium dependent mitochondrial permeability transitionleading to dysfunction in vitro. Toxicology2010.275,1–9.
16.Tan HH, Ong WMC, Lai SH, et al. Nimesulide-induced hepatotoxicityand fatal hepatic failure. Singapore Med2007;48(6):582.
17.Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicityassociated with nimesulide and other non-steroidal anti-inflammatorydrugs. BMJ2003;327(7405):18-22.
18.陈健，黄媛恒，王乃平，等.玉郎伞多糖和皂苷对氧自由基清除作用研究[J].中药药理与临床,2007,23(5).
19.段小群,焦杨,张士军,等.玉郎伞多糖对肝星状细胞增殖和l型胶原合成的影响[J].中国现代医学杂志,2008,18(4):423-425.
20.方允中,郑荣梁.自由基生物学的理论与应用[M].北京:科学出版社,2002，13-15.
21.付书婕，王乃平，黄仁彬.植物多糖免疫调节作用的研究进展.《时珍国医国药》2008;19(1):99-101.
22.付书婕.玉郎伞多糖对小鼠肝损伤的作用及其机制研究.南宁：广西医科大学.2008.
23.黄仁彬,段小群,焦阳,等.玉郎伞提取物对小鼠化学性损伤保护作用及其机制的研究[J].广西医科大学学报,2003,22(6):874-875.
24.黄必义,黄仁彬,卢曦,等.玉郎伞多糖对肝星状细胞氧应激脂质过氧化作用的影响[J].时珍国医国药,2008,19(4):814-815.
25.Adamson GM, Billings RE. Tumor necrosis factor induced oxidativestress in isolated mouse hepatocytes. Arch Biochem Biophys,1992;294(1):223-229.
26.藏国庆，周霞秋，俞红，等.肿瘤坏死因子2α诱导肝细胞凋亡在暴发性肝衰竭中的作用.中华消化杂志,2000;20(3):163.
27.Kem MC. Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet,2000;355(204):591-592.
28.Mizuhara H, Uno M, Seki Y. Critical involvement of interferon gamma inthe pathogenesis of T-cell activation-associated hepatitis and regulatorymechanisms of interleukin-6for the manifestations of hepatitis.Hepatology,1996;23(6):1608-1615.
29.Pauli U. Porcine TNF: a review. Vet Immunol Immunopathol,1995;47(3-4):187-201.
30.Sheu SS, Nauduri D, Anders MW. Targeting antioxidants tomitochondria:a therapeutic direction. Biochimica et Biophysica Acta20061762,256–265.
31.Tiegs G, Kusters S, Kunstle G, et al. Ebselen protects mice against T-celldependent TNF-mediated apoptotic liver injury, Journal of Pharmacologyand Experimental Therapeutics,1998;287(3):1098-1104.
32.Tiegs G. Experimental hepatitis and role of cytokines. Acta GastroenterolBelg,1997;60(2):176-179.
33.Adams JM, Cory S. Life or death decisions by the Bcl-2protein family.Trends Biochem Sic,2001;26(1):61-66.
34.Delft MF, Huang DC. How the Bcl-2family of proteins interact toregulate apoptosis. Cell Res,2006;16(2):203-213.
35.Goga LM, Vasiliu OM, Ionescu CR. Molecular mechanisms of apoptosis.Fas and TNF systems ICE protease system. Bcl-2family. Rev Med ChirSoc Med Nat Iasi,2001;105(1):23-29.
36.Greenwald RA.1985. CRC Handbook of Methods for Oxygen RadicalResearch.1st Edn., CRC Press, Boca Raton, Florida, ISBN:0849329361,pp:447.
37.Han YH, Kim SH, Kim H, et al. Intracellular GSH levels rather than ROSlevels are tightly related to AMA induced HeLa cell death.Chemico-Biological Interactions2008.171,67–78.
38.Kaplowit ZN. Mechanism of liver cell injury. J Hepatol，2000;32(1Suppl):39-47.
39.Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
40.Kukhta VK, Marozkina NV, Sokolchik IG, et al. Molecular mechanismsof apoptosis. Ukr Biokhim Zh,2003;75(6):5-9.
41.李勇，孔令青，高洪，等.自由基与疾病研究进展.动物医学进展，2008；29（4）：85-87.
42.Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis.1996;16(4):357-367.
43.Machy TJ, Borkowski A, Amin, et al. Bc1-2/Bax ratio as a predictivemarker for the rapeutic response to radiotherapy in patients with prostatecancer. Urologe,1998;56(2):1085.
44.Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat RevMol Cell Biol,2001;2(1):63-7.
45.Orrenius S. Reactive oxygen species in mitochondria-mediated cell death.Drug Metabolism Reviews2007，39,443–455.
46.Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due tomitochondrial dysfunction. Cell Biol Toxicol.1999;15(6):367-73.
47.Sastre J, Serviddio G, Pereda J, et al. Mitochondrial function in liverdisease. Front Biosci,2007;12:1200-9.
48.Tripathi M, Singh BK, Raisuddin S, et al. Abrogation of nimesulideinduced oxidative stress and mitochondria mediated apoptosis by Fumariaparviflora Lam. extract. J Ethnopharmacol,2011;136(1):94-102.
49.William ML. Drug-Induced Hepatotoxicity [J]. The New EnglandJournal of Medicine2003;349:474-85.
50.徐叔云，卞如濂，陈修.药理实验方法学（第三版），北京：人民卫生出版社.2002；227-228.
1. Aithal GP. Hepatotoxicity related to antirheumatic drugs [J]. Nat RevRheumatol,2011；7(3)：139-50.
2. García Rodríguez LA, Williams R, Derby LE, et al. Acute liver injuryassociated with nonsteroidal anti-inflammatory drugs and the role of riskfactors. Arch Intern Med,1994;154(3):311-6.
3. García Rodríguez LA，Pérez Gutthann S，Walker AM, et al. The role ofnon-steroidal anti-inflammatory drugs in acute liver injury [J]。BMJ1992；305(6858)：865–868.
4. Grattagliano I，Portincasa P，Palmieri VO, et al. Overview on themechanisms of drug-induced liver cell death。Ann Hepatol2002；1(4)：162-8.
5. Lapeyre-Mestre M, de Castro AM, Bareille MP, et al. Non-steroidalanti-inflammatory drug-related hepatic damage in France and Spain:analysis from national spontaneous reporting systems. Fundam ClinPharmacol,2006;20(4):391-5.
6. Michael PH，Cynthia J. Mechanisms of Drug-Induced Liver Injury.AAPS J2006；8(1)：48–54.
7. O'Connor N, Dargan PI, Jones AL. Hepatocellular damage fromnon-steroidal anti-inflammatory drugs. QJM,2003;96(11):787-91.
8. Walker AM. Quantitative studies of the risk of serious hepatic injury inpersons using nonsteroidal anti-inflammatory drugs[J]。Arthritis Rheum1997；40:201-208.
9. William ML. Drug-Induced Hepatotoxicity [J]. The New England Journalof Medicine2003；349：474-85.
10.Bennett WE，Turmelle YP，Shepherd RW. Ibuprofen-Induced Liver Injuryin an Adolescent Athlete。ClinPediatr (Phila)2009；48(1)：84-6.
11.Cazanave S, Vadrot N, Tinel M, et al. Ibuprofen administration attenuatesserum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosisand mouse mortality after Fas stimulation. Toxicol Appl Pharmacol,2008;231(3):336-43.
12.Ilic S，Drmic D，Zarkovic K，et al. Ibuprofen hepatic encephalopathy，hepatomegaly，gastric lesion and gastric pentadecapeptide BPC157inrats [J]. Eur J Pharmacol2011；667(1-3)：322-9.
13.Mahalakshmi R, Rajesh P, Ramesh N, et al. Hepatoprotective Activity onVitex negundo Linn.(Verbenaceae) by using Wistar Albino Rats inIbuprofen Induced Model. International Journal of Pharmacology,2010,6:658-663.
14.Moorthy M，Fakurazi S and Ithnin H. The Histomorphological Analysisof Liver Following Administration of Low Doses of Diclofenac andIbuprofen [J]. Journal of Biological Sciences2009；9(7)：676-681.
15.Mu oz-García A. Ibuprofen-associated hepatotoxicity: Analysis of caseseries included in the Spanish DILI registry. Journal of Hepatology2011；54：206.
16.Rainsford KD. Ibuprofen: pharmacology， efficacy and safety.Inflammopharmacology2009；17(6)：275-342.
17.王淑英,倪国栋.布洛芬致急性重症肝炎1例[J].中国临床药学杂志2000；9(5)：316.
18.陈健,黄媛恒,王乃平,等.玉郎伞多糖和皂苷对氧自由基清除作用研究[J]。中药药理与临床2007；23(5)：100.
19.段小群,焦杨,张士军,等.玉郎伞多糖对肝星状细胞增殖和l型胶原合成的影响[J].中国现代医学杂志,2008,18(4):423-425.
20.广西壮族自治区卫生厅.广西中药材标准［S］南宁：广西科学技术出版社，1990：166.
21.付书婕，黄建春，王乃平，等.玉郎伞多糖对小鼠急性酒精性肝损伤保护作用的研究[J].中国药房2009；20(6)：406.
22.黄仁彬，段小群，焦杨等.玉郎伞提取物对小鼠急性化学性肝损伤保护作用及其机制的研究[J]。广西医科大学学报2003；20(6)：874.
23.黄必义,黄仁彬,卢曦,等.玉郎伞多糖对肝星状细胞氧应激脂质过氧化作用的影响[J].时珍国医国药,2008,19(4):814-815.
24.付书婕.玉郎伞多糖对小鼠肝损伤的作用及其机制研究.南宁：广西医科大学.2008.
25.黄正明，杨新波，曹文斌，等.化学性及免疫性肝损伤模型的方法学研究.解放军药学学报，2005；21（1）：33-38.
26.Adamson GM, Billings RE. Tumor necrosis factor induced oxidativestress in isolated mouse hepatocytes. Arch Biochem Biophys,1992;294(1):223-229.
27.方允中,郑荣梁.自由基生物学的理论与应用[M].北京:科学出版社,2002，13-15.
28.李勇，孔令青，高洪，等.自由基与疾病研究进展.动物医学进展，2008；29（4）：85-87.
29.Kem MC. Serum aminotransferase concentration as evidence ofhepatocellular damage. Lancet,2000;355(204):591-592.
30.Tiegs G. Experimental hepatitis and role of cytokines. Acta GastroenterolBelg,1997;60(2):176-179.
31.张晓静,刘会东.植物多糖提取分离及药理作用的研究进展〔J〕.时珍国医国药.2(X)3,14(8):495-497。
32.Adams JM, Cory S. Life or death decisions by the Bcl-2protein family.Trends Biochem Sic,2001;26(1):61-66.
33.Delft MF, Huang DC. How the Bcl-2family of proteins interact toregulate apoptosis. Cell Res,2006;16(2):203-213.
34.Goga LM, Vasiliu OM, Ionescu CR. Molecular mechanisms of apoptosis.Fas and TNF systems. ICE protease system. Bcl-2family. Rev Med ChirSoc Med Nat Iasi,2001;105(1):23-29.
35.Kaplowit ZN. Mechanism of liver cell injury. J Hepatol,2000;32(1Suppl):39-47.
36.Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
37.Kukhta VK, Marozkina NV, Sokolchik IG, et al. Molecular mechanismsof apoptosis. Ukr Biokhim Zh,2003;75(6):5-9.
38.Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury throughmitochondrial dysfunction: mechanisms and detection during preclinicalsafety studies. Fundam Clin Pharmacol.2008Aug;22(4):335-53.
39.Losser MR, Payen D. Mechanisms of liver damage. Semin Liver Dis.1996;16(4):357-367.
40.Machy TJ, Borkowski A, Amin, et al. Bc1-2/Bax ratio as a predictivemarker for the rapeutic response to radiotherapy in patients with prostatecancer. Urologe,1998;56(2):1085.
41.Pessayre D, Mansouri A, Haouzi D, et al. Hepatotoxicity due tomitochondrial dysfunction. Cell Biol Toxicol.1999;15(6):367-73.
42.Rekka E, Ayalogu EO, Lewis DF, et al. Induction of hepatic microsomalCYP4A activity and of peroxisomal beta-oxidation by two non-steroidalanti-inflammatory drugs. Arch Toxicol.1994;68(2):73-8.
43.Sastre J, Serviddio G, Pereda J, et al. Mitochondrial function in liverdisease. Front Biosci,2007;12:1200-9.
44.汤新慧，高静.实验性肝损伤的损伤机制.中西医结合肝病杂志,2002；12（1）：53-55.
45.徐叔云，卞如濂，陈修.药理实验方法学（第三版），北京：人民卫生出版社.2002；227-228.
1. Aithal GP. Hepatotoxicity related to antirheumatic drugs [J]. Nat RevRheumatol,2011；7(3)：139-50.
2. Aithal GP, Watkins PB, Andrade RJ, et al. Case definition andphenotype standardization in drug-induced liver injury (DILI). ClinPharmacol Ther2011.
3. Andrade RJ, Robles M, Fernandez-Castaner A, et al. Assessment ofdrug-induced hepatotoxicity in clinical practice: a challenge forgas-troenterologists[J]. World J Gastroenterol,2007,13(3):329.
4.白汉玉．药源性肝损害［J］．中级医刊，1994，29(2):11-13．
5. Betrosian AP, Flevari K, Andrianakis I, et al. Severe hemolytic anemiaand fatal hepatic failure associated with nimesulide. Dig Liver Dis.2009;41(1):80.
6. Berson A, Cazanave S, Descatoire V, et al. The anti-inflammatory drug,nimesulide (4-nitro-2-phenoxymethane-sulfoanilide), uncouplesmitochondria and induces mitochondrial permeability transition inhuman hepatoma cells: protection by albumin. J Pharmacol Exp Ther,2006;318(1):444-54.
7. Buratti S, Lavine JE. Drugs and the liver:advances in metadbolism,toxicity, and the rapeutics[J].Curr Opin Pediatr,2002,14(5):601.
8. Cantoni L, Valaperta R, Ponsoda X, et al. Induction of hepatic hemeoxygenase-1by diclofenac in rodents: role of oxidative stress andcytochrome P450activity. Journal of Hepatology,2003;38(6):776-83.
9. Cazanave S, Vadrot N, Tinel M, et al. Ibuprofen administrationattenuates serum TNF-alpha levels, hepatic glutathione depletion,hepatic apoptosis and mouse mortality after Fas stimulation. ToxicolAppl Pharmacol,2008;231(3):336-43.
10.陈成伟.药物与中毒性肝病.第一版.上海科学技术出版社.2002,4-5.
11.陈一凡，蔡皓东．中药引起肝损害的调查分析［J］．药物不良反应杂志，1999，1(1)：27-32．
12.García Rodríguez LA，Pérez Gutthann S，Walker AM, et al. The roleof non-steroidal anti-inflammatory drugs in acute liver injury[J]. BMJ,1992；305(6858)：865–868.
13.侯鹏鹏,药物性肝炎研究进展,[J]医学理论与实践2008;8(21):899-890.
14.Ilic S，Drmic D，Zarkovic K，et al. Ibuprofen hepatic encephalopathy，hepatomegaly，gastric lesion and gastric pentadecapeptide BPC157inrats [J]. Eur J Pharmacol2011；667(1-3)：322-9.
15.贾继东,崔儒涛.非甾体抗炎药的肝脏毒性[J].肝脏,2001,6(1):50.
16.Kaplowit ZN. Mechanism of liver cell injury. J Hepatol,2000;32(1Suppl):39-47.
17.Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of celldeath. Cancer Chemother Pharmacol,2006;57(5):545-553.
18.李慧敏,赵叶丽.药物性肝炎65例临床分析[J].浙江中西医结合杂志,2003,13(3):169-170.
19.厉有名.药物性肝损害的临床类型及诊断策略.中华肝脏病杂志,2004,12:445-446.
20.Losser MR, Payen D. Mechanisms of liver damage. Semin LiverDis.1996;16(4):357-367.
21.陆玮婷，李军，欧宁，等．72例中药引起药物性肝损的临床研究［J］．江苏医药，2007，33(6)：546-547．
22.Malcolm A, Steele MD. Toxic hepatitis with isoniazid and rifampin ameta-analysis[J]. Chest,1999,2:465~471.
23.Maria VA, Victtorino RM. Development and validation of a clinicalscale for the diagnosis of drug-induced hepatitis.Hepatology,1997,26:664-669.
24.Masubuchi Y, Nakayama S, Horie T. Role of mitochondrialpermeability transition in diclofenac-induced hepatocyte injury in rats.Hepatology,2002;35(3):544-51.
25.Merlani G, Fox M, Oehen HP, et al. Fatal hepatoxicity secondary tonimesulide [J]. Eur J Clin Pharmacol2001;57(4):321-6.
26.Mingatto FE, Rodrigues T, Pigoso AA, et al. The critical role ofmitochondrial energetic impairment in the toxicity of nimesulide tohepatocytes. J Pharmacol Exp Ther,2002;303(2):601-7.
27.Monteiro JP, Marti ns AF, Lúcio M, et al. Nimesulide interaction withmembrane model systems: Are membrane physical effects involved innimesulide mitochondrial toxicity?[J]. Toxicol In Vitro2011;25(6):1215-23.
28.Mu oz-García A. Ibuprofen-associated hepatotoxicity: Analysis ofcase series included in the Spanish DILI registry. Journal ofHepatology2011；54：206.
29.茅益民,曾民德.药品评价.2007;4(6):389.
30.钱又宏,姚光弼.药物性肝病的病因和临床表现43例分析[J].肝脏,2000,1(3):166-169.
31.Roberts RA, Ganey PE, Cynthia Ju, et al. Role of the kupffer cell inmediating hepatic toxicity and carcinogensis. Toxic Sci,2006;96(1):2-15.
32.Robin MA, LeRoy M, Descatoire V, et al. Plasma membranecytochromes P450s neoantigens and autoinunune targets indrug-induced hepatitis[J]. J Hepatol,1997,26(suppl1):23.
33.宋建华．药物性肝病40例临床分析［J］．药学服务与研究，2005，5(3)：282．
34.Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injuryin Japan: an analysis of1676cases between1997and
2006.Hepatology Res2009;39:427-31.
35.杨冰华，张轶停，张春艳，等．药物性肝损害［J］．临床和实验医学杂志，2003，2(1)：62-64．
36.姚光弼.重视中药和草药引起的肝损害.肝脏,2005,10(1):1.
37.袁海鹏，李廷青．药物性肝病的发病机制及治疗[J]．山东医药，2004，4(10)：54—55．
38.张涛，贾继东．107例药物性肝损害的病因和临床特点［J］．肝脏，2005，10(3)：174-176．
39.张惠芸.腺苷蛋氨酸治疗慢性肝炎及肝炎肝硬化的疗效[J]中国临床药学杂志,2000,9(6):335-338.
40.赵凤芹,王江滨.抗结核药物诱导肝损伤的评价[J].国外医学呼吸系统分册,2003,23(6):322-324.
41.周艳莉，杨毅恒．中成药致肝损害401例分析［J］．中国药物应用与监测，2007，4(4)：6-8．
42.王凡,刘宾,李莉,等.急性药物性肝损害的临床分析和治疗探讨[J].中国医院用药评价与分析,2007,7(3):193-195.
43.萬古直,张临详译.传统草药(“汉方药”)与药物性肝损害[J].日报医.
44.汪云,朱丽影.药物性肝炎的发病机制[J].黑龙江医学,2008,32(5):34;342.
45.王伟芳，陈一华．药物性肝损害及其预防［J］．临床肝胆病杂志，1993，9(3)：124-127．
46. Wang Z, Liang X, Yu J, et al. Non-genetic risk factors and predictingefficacy for docetaxel-drug-induced liver injury among metastatic breastcancer patients[J].J Gastroenterol Hepatol,2012,27(8):1348-1352.
47.Walker AM. Quantitative studies of the risk of serious hepatic injuryin persons using nonsteroidal anti-inflammatory drugs[J]. ArthritisRheum1997；40:201-208.
48.William ML. Drug-Induced Hepatotoxicity [J]. The New EnglandJournal of Medicine2003；349：474-85.
1.国家药典委员会.卫生部药品标准中药成方制剂.第十二册.1997:161.
2.蒋伟哲，孔晓龙，段小群，等.龙眼参对机体氧自由基清除作用的研究[J].中国药房，2011,12（8）：543-455.
3.荣延平，黄仁彬，陈晓宇,等.玉郎伞多糖提取工艺的正交法优化[J].时珍国医国药,2012，23(3):567-569.
4.黄仁斌，林兴，蒋伟哲，等.玉郎伞化学成分对自发性高血压大鼠血压的影响[J].中国医院药学杂志，2006,26（2）：130-132.
5.段小群，焦扬，黄仁斌，等.玉郎伞提取物对大鼠自发性高血压的影响[J].广西医科大学学报，2003,20（1）：18.
6.黄仁彬,吕纪华,张绪东,等.玉郎伞黄酮类化合物对大鼠离体心脏缺血再灌注损伤的作用[J].华西药学杂志,2010，25(3):287-289.
7.吕纪华,贺敏,黄建春,等.玉郎伞黄酮对心肌缺血再灌注损伤心肌组织ATP酶和凋亡蛋白的影响[J].中国实验方剂学杂志,2010，16(13):162-166.
8.李健玲,陈兆霓,吕纪华,等.玉郎伞皂苷对大鼠离体心脏缺血再灌注损伤的保护作用[J].中国实验方剂学杂志,2012，18(9):250-253.
9.陈丽,张士军,黄建春,等.玉郎伞提取物对高脂血症大鼠血液流变学的影响[J].华西药学杂志,2012，22：41-44.
10.陈丽,黄仁彬,张绪东,等.玉郎伞总黄酮对洛伐他汀降血脂的增效作用研究[J].中成药,2013，35(2):225-228.
11.覃斐章，简洁，焦杨，等.YLSC对心肌缺血再灌注损伤细胞ASK1、Cyt-C、Bcl-2、Bax蛋白表达的影响[J].山东医药,2012，52：39-41.
12.简洁,刘曦,黄仁彬，等.玉郎伞2种查尔酮单体对心肌过氧化损伤的保护作用研究[J].中国药房,2010，21：2124-2126.
13.简洁，黄仁彬.玉郎伞2，6-二甲氧基查尔酮含药血清对心肌细胞氧化损伤的影响[J].中国现代医学杂志,2011，21(15):1809-1813.
14.段小群,焦杨,张士军,等.玉郎伞多糖对肝星状细胞增殖和I型胶原合成的影响[J].中国现代医学杂志,2008，18(4):423-425.
15.梁颖娥，付书婕，贝学室.玉郎伞多糖解酒作用及机制研究[J].时珍国医国药,2011，22(11):2651-2652.
16.黄媛恒，陈健，黄仁彬,等.玉郎伞提取物对模型大鼠胸膜炎TNF-α、PGE2、NO的影响[J].中国药房,2010,21(3):200-202.
17.陈丽，张绪东，焦杨,等.玉郎伞提取物对食饵性高脂血症大鼠肝脏脂蛋白代谢相关酶活性及脂肪肝的影响[J].中国实验方剂学杂志,2012，18(9):254-258.
18.郭又嘉,文坎，张士军,等.玉郎伞皂苷对四氯化碳诱导大鼠肝纤维化的影响[J].中国药理学通报,2012，28(4):554-558.
19.文坎，郭又嘉，蒙明瑜,等.玉郎伞黄酮对四氯化碳诱导小鼠急性肝损伤的保护作用[J].中国实验方剂学杂志,2012，18(16):269-272.
20.郭又嘉，蒙明瑜，焦杨,等.玉郎伞黄酮对四氯化碳诱导的大鼠肝纤维化的影响[J].中国实验方剂学杂志,2012，18(16):198-202.
21.陈晓宇，荣延平，张士军,等.玉郎伞多糖对Aβ25-35诱导PC12细胞损伤的保护作用研究[J].中国药房,2013，24(19):1735-1737.